143 related articles for article (PubMed ID: 26191263)
21. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
23. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
[TBL] [Abstract][Full Text] [Related]
24. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract.
Hirano D; Okada Y; Nagane Y; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Kawata N; Takahashi S; Henmi A
Urol Int; 2012; 89(1):71-7. PubMed ID: 22677699
[TBL] [Abstract][Full Text] [Related]
25. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection.
Espiritu PN; Sverrisson EF; Sexton WJ; Pow-Sang JM; Poch MA; Dhillon J; Spiess PE
Urol Oncol; 2014 Jul; 32(5):619-24. PubMed ID: 24495448
[TBL] [Abstract][Full Text] [Related]
26. Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections.
Castellini P; Montironi MA; Zizzi A; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Paone N; Montironi R
Hum Pathol; 2014 Apr; 45(4):745-52. PubMed ID: 24565208
[TBL] [Abstract][Full Text] [Related]
27. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
28. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
29. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
30. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification.
Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI
J Urol; 2005 Nov; 174(5):1976-80. PubMed ID: 16217372
[TBL] [Abstract][Full Text] [Related]
31. De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study.
Palazzetti A; Bosio A; Dalmasso E; Destefanis P; Fop F; Pisano F; Segoloni G; Biancone L; Volpe A; Di Domenico A; Terrone C; Iesari S; Famulari A; Todeschini P; Frea B; Gontero P
Urol Int; 2018; 100(2):185-192. PubMed ID: 29342465
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
Jones TD; Cheng L
Urol Oncol; 2021 May; 39(5):286-290. PubMed ID: 35550107
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
[TBL] [Abstract][Full Text] [Related]
34. Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China.
Wang Q; Zhang T; Wu J; Wen J; Tao D; Wan T; Zhu W
BMC Urol; 2019 Apr; 19(1):24. PubMed ID: 30999871
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population: A Retrospective Study.
Shen Z; Xie L; Chen T; Tian D; Liu X; Xu H; Zhang Y; Wu Z; Sha N; Xing C; Ding N; Hu H; Wu C
Medicine (Baltimore); 2016 Feb; 95(5):e2625. PubMed ID: 26844474
[TBL] [Abstract][Full Text] [Related]
37. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
38. Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer.
Li X; Shu K; Zhou J; Yu Q; Cui S; Liu J; Zhou R; Ding D
Clin Genitourin Cancer; 2020 Feb; 18(1):11-19.e1. PubMed ID: 31787543
[TBL] [Abstract][Full Text] [Related]
39. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder.
Cheng L; MacLennan GT; Zhang S; Wang M; Pan CX; Koch MO
Cancer; 2004 Jul; 101(1):183-8. PubMed ID: 15222005
[TBL] [Abstract][Full Text] [Related]
40. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
